After news came out that Moderna has been secretly working on a Hantavirus vaccine, the MRNA share price rocketed +5% ...

This development renewed investor confidence in Moderna’s mRNA pipeline, even as a cluster of hantavirus cases emerged on a ...

Novavax (NVAX) is in focus after outlining a move toward a licensing and royalty model, supported by partnerships with Sanofi and Pfizer, while investors watch for a Phase 3 COVID influenza combo ...

Moderna stock fell on Wednesday after the vaccine maker said the Food and Drug Administration refused to review its application to sell a new seasonal flu vaccine. The biotech company closed the day ...

Moderna (MRNA) is back in focus after its Q1 2026 earnings, reporting revenue of US$389 million compared with US$108 million ...

New phase 2 data from personalized cancer vaccine EVX-01 demonstrates a record-high rate of vaccine targets triggering a tumor-specific immune response The results reinforce that Evaxion’s pioneering ...

See more on Vaxcyte's (PCVX) and VAX-31’s broad pneumococcal vaccine pipeline, strong cash runway, and key 2026–2027 trial ...

Is NVAX a good stock to buy? We came across a bullish thesis on Novavax, Inc. on BioEquity Watch’s Substack. In this article, ...

Looking to invest in biotech stocks? Learn what they are, explore top options, and find out how to get started in this fast-growing, exciting industry.